Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP1 | P03956 | 2/20 | 0.49 |
| ▸ | MMP9 | P14780 | 2/20 | 0.49 |
| ▸ | MMP13 | P45452 | 2/20 | 0.49 |
| ▸ | GPR119 | Q8TDV5 | 10/20 | 0.44 |
| ▸ | MMP3 | P08254 | 1/20 | 0.44 |
| ▸ | MMP7 | P09237 | 1/20 | 0.44 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | ROCK2 | O75116 | 6/20 | 0.42 |
| ▸ | ROCK1 | Q13464 | 6/20 | 0.42 |
| ▸ | JAK2 | O60674 | 1/20 | 0.39 |
| ▸ | JAK3 | P52333 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL567645 | 1.00 | MMP1 (0.49) | MMP1MMP9MMP13GPR119MMP3 | |
| SCHEMBL567644 | 1.00 | MMP1 (0.49) | MMP1MMP9MMP13GPR119MMP3 | |
| SCHEMBL567358 | 0.99 | MMP1 (0.48) | MMP1MMP9MMP13GPR119MMP3 | |
| SCHEMBL567256 | 0.99 | MMP1 (0.48) | MMP1MMP9MMP13GPR119MMP3 | |
| SCHEMBL567257 | 0.99 | MMP1 (0.48) | MMP1MMP9MMP13GPR119MMP3 | |
| SCHEMBL567993 | 0.98 | MMP13 (0.51) | MMP1MMP9MMP13GPR119MMP3 | |
| SCHEMBL567577 | 0.98 | MMP13 (0.51) | MMP1MMP9MMP13GPR119MMP3 | |
| SCHEMBL567576 | 0.98 | MMP13 (0.51) | MMP1MMP9MMP13GPR119MMP3 | |
| SCHEMBL568116 | 0.94 | MMP1 (0.49) | MMP1MMP9MMP13GPR119MMP3 | |
| SCHEMBL568117 | 0.94 | MMP1 (0.49) | MMP1MMP9MMP13GPR119MMP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12286417-B2 | 1,4-diazocane compound or salt thereof | D. WESTERN THERAPEUTICS INSTITUTE, INC. (JP) | 2025-04-29 | — | — | US | disclosed |
| US-20210371396-A1 | 1,4-DIAZOCANE COMPOUND OR SALT THEREOF | D. WESTERN THERAPEUTICS INSTITUTE, INC. (JP) | 2021-12-02 | — | — | US | disclosed |
| US-20210371396-A1 | 1,4-DIAZOCANE COMPOUND OR SALT THEREOF | D. WESTERN THERAPEUTICS INSTITUTE, INC. (JP) | 2021-12-02 | — | — | US | disclosed |
| EP-3875449-A1 | 1,4-DIAZOCANE COMPOUND OR SALT THEREOF | D. Western Therapeutics Institute, Inc. (JP) | 2021-09-08 | — | — | EP | disclosed |
| EP-3875449-A1 | 1,4-DIAZOCANE COMPOUND OR SALT THEREOF | D. Western Therapeutics Institute, Inc. (JP) | 2021-09-08 | — | — | EP | disclosed |
| CN-113166044-A | 1, 4-diazacyclooctane compounds or salts thereof | 株式会社D.西医疗法研究所 | 2021-07-23 | — | — | CN | disclosed |
| EP-2444395-B1 | SUBSTITUTED ISOQUINOLINE DERIVATIVE | WESTERN THERAPEUTICS INST INC D (JP) | 2016-01-06 | — | — | EP | disclosed |
| EP-2444395-B1 | SUBSTITUTED ISOQUINOLINE DERIVATIVE | WESTERN THERAPEUTICS INST INC D (JP) | 2016-01-06 | — | — | EP | disclosed |
| US-8951997-B2 | Substituted isoquinoline derivative | D. WESTERN THERAPEUTICS INSTITUTE, INC. (JP) | 2015-02-10 | — | — | US | disclosed |
| EP-2444395-A1 | SUBSTITUTED ISOQUINOLINE DERIVATIVE | D. Western Therapeutics Institute, Inc. (JP) | 2012-04-25 | — | — | EP | disclosed |
| EP-2444395-A1 | SUBSTITUTED ISOQUINOLINE DERIVATIVE | D. Western Therapeutics Institute, Inc. (JP) | 2012-04-25 | — | — | EP | disclosed |
| US-20120035159-A1 | SUBSTITUTED ISOQUINOLINE DERIVATIVE | D. WESTERN THERAPEUTICS INSTITUTE, INC (JP) | 2012-02-09 | — | — | US | disclosed |
| WO-2010146881-A1 | SUBSTITUTED ISOQUINOLINE DERIVATIVE | 株式会社デ・ウエスタン・セラピテクス研究所 (JP) | 2010-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12286417-B2 | 1,4-diazocane compound or salt thereof | SULT1E1, SULT1A1, SULT2A1 | MMP1 3549/4885MMP9 2500/4885MMP13 4719/4885 |
| US-20120035159-A1 | SUBSTITUTED ISOQUINOLINE DERIVATIVE | SULT1A1, SULT1E1, SULT2A1 | MMP1 4000/4885MMP9 4791/4885MMP13 4729/4885 |
| US-20210371396-A1 | 1,4-DIAZOCANE COMPOUND OR SALT THEREOF | SULT1E1, SULT1A1, SULT2A1 | MMP1 3549/4885MMP9 2500/4885MMP13 4719/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.